RenalytixRENXF Days Payable is 901.09 as of Dec. 2025, which is 87% above its 10-year median of 482.95. The stock has 3 warning signs investors should review. Among 607 Healthcare Providers & Services companies, Renalytix ranks better than 96.05% on this metric.
Renalytix's average Accounts Payable for the
six
months ended in Dec. 2025 was $3.95 Mil. Renalytix's Cost of Goods Sold for the
six
months ended in Dec. 2025 was $0.80 Mil.
Hence, Renalytix's Days Payable for the
six
months ended in Dec. 2025 was 901.09.
The historical rank and industry rank for Renalytix's Days Payable or its related term are showing as below:
RENXF'
s Days Payable Range Over the Past 10 Years
Min: 349.02 Med: 482.95 Max: 966.01
Current: 868.08
During the past 8 years, Renalytix's highest Days Payable was 966.01. The lowest was 349.02. And the median was 482.95.
RENXF's Days Payable is ranked better than 96.05% of 607
companies
in the Healthcare Providers & Services industry
Industry Median: 58.16
vs RENXF: 868.08
Renalytix's Days Payable
increased
from Dec. 2024 (821.82) to Dec. 2025 (901.09).
It may suggest that Renalytixdelayed paying its suppliers.
Renalytix Days Payable Related Terms
Renalytix Days Payable Historical Data
* Premium members only.
The historical data trend for Renalytix's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Renalytix's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Renalytix Days Payable vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Renalytix's Days Payable distribution charts can be found below:
* The bar in red indicates where Renalytix's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Renalytix's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Renalytix (RENXF) has a Days Payable of 901.09 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Renalytix and its competitors. This is 87% above median its historical median of 482.95. Over the past decade, Renalytix's Days Payable has ranged from 349.02 to 966.01. According to the industry distribution chart, Renalytix ranks #24 out of 607 companies in the Healthcare Providers & Services industry, placing it in the top 4%.
Is Renalytix's Days Payable too high?
Renalytix's current Days Payable of 901.09 is 87% above median its 10-year median of 482.95. Over the past 10 years, this metric has ranged from a low of 349.02 to a high of 966.01. The Healthcare Providers & Services industry median Days Payable is 58.16. Renalytix's value of 901.09 is 1449.3% above this industry median. Based on the distribution chart, Renalytix ranks #24 out of 607 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers.
How does Renalytix's Days Payable compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Renalytix ranks #24 out of 607 companies for Days Payable. This places Renalytix in the top 4% of its industry — outperforming the majority of peers. The industry median Days Payable is 58.16. Renalytix's value of 901.09 is 1449.3% above this benchmark. Historically, Renalytix's own Days Payable has ranged from 349.02 to 966.01 over the past decade. While the company's 10-year median is 482.95 vs. the industry median of 58.16, Renalytix has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Healthcare Providers & Services company?
The median Days Payable among Healthcare Providers & Services companies is 58.16, based on 607 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Renalytix's current Days Payable of 901.09 is 1449.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Renalytix and its competitors. For the Healthcare Providers & Services industry, the median Days Payable is 58.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Renalytix's current Days Payable is 901.09, which is 87% above median its own 10-year median of 482.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renalytix stock overvalued right now?
Based on GuruFocus' analysis, Renalytix (RENXF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.06, compared to a current price of $0.04 — trading 39.8% below its estimated fair value. The current Days Payable is 901.09, which is 87% above median its 10-year median of 482.95 and 1449.3% above the Healthcare Providers & Services industry median of 58.16. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Renalytix (RENXF), the current Days Payable is 901.09 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease. Its product, KidneyIntelX, is designed to improve kidney disease diagnosis and prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company's service, KidneyIntelX.dkd, enables the assessment of risk for early-stage chronic kidney disease progression. KidneyIntelX uses a proprietary algorithm combining blood-based biomarkers, inherited genetics, and electronic health record data to generate a patient risk score predicting rapid kidney function decline.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RENXF has been successfully added to your 